<DOC>
	<DOC>NCT02642432</DOC>
	<brief_summary>The purpose of this study is to assess the safety and efficacy of ABT-493/ABT-530 following 12 weeks of treatment in adults with chronic Hepatitis C Virus Infection genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>Screening laboratory result indicating hepatitis C virus (HCV) Genotype 1, 2, 4, 5 or 6 infection Chronic HCV infection Subject must be HCV treatmentna√Øve or have failed prior HCV treatment Subject must have documented compensated cirrhosis and no current or past clinical evidence of decompensated liver disease Positive test result at screening for Hepatitis B surface antigen or antihuman immunodeficiency virus antibody HCV genotype performed during screening indicating coinfection with more than 1 HCV genotype Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive ABT493/ABT530</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HCV Genotype 1</keyword>
	<keyword>HCV Genotype 4</keyword>
	<keyword>HCV Genotype 2</keyword>
	<keyword>Cirrhotic</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>Compensated Cirrhosis</keyword>
	<keyword>HCV Genotype 5</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV Genotype 6</keyword>
</DOC>